Paeds Cases · ophthalmology
Explaining progressive myopia and myopia control to a family — OSCE
Communication and structured-discussion OSCE on progressive myopia in an 8-year-old girl, covering the optical basis of myopia, why cycloplegic refraction confirms the prescription, the stepwise management with spectacles plus myopia control (outdoor time, reduced near work, low-dose atropine 0.05 percent from the LAMP trial, orthokeratology and defocus lenses), the reassurance that under-correction does not slow progression, and the red flags that would prompt urgent referral.
On this page
Study tools
Target exams
Candidate instructions (8-minute station)
You are the paediatric registrar in clinic. An 8-year-old girl has six months of squinting at the board and worsening distance vision. Both her parents wear glasses for short-sightedness, and she spends most of the day on screens with little outdoor time. Her distance vision improves to normal with a pinhole. The family has read about "atropine drops to stop myopia" and asks whether she should start them today. [1]
Your tasks are: [10]
- Explain the likely diagnosis — myopia — in plain language, and why both parents being short-sighted and the screen time fit the picture. [1]
- Explain why a cycloplegic refraction comes before the final prescription, and what that test involves. [10]
- Outline the treatment — spectacles for clear distance vision, plus myopia control built on outdoor time and reduced near work, with low-dose atropine, orthokeratology or defocus lenses as options — and explain why deliberately under-correcting the glasses is not advised. [12]
- Address the atropine question honestly — what the LAMP trial showed about 0.05 percent being the most effective of the low doses — and name the red flags that would bring her back sooner. [4]
You are not expected to start atropine in this station — the cycloplegic refraction and the shared decision with the family and ophthalmology come first. [5]
References5ShowHide
- [1]Holden BA; Fricke TR; Wilson DA; Jong M; et al Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology, 2016.PMID 26875007
- [4]Yam JC; Jiang Y; Tang SM; Law AKP; et al Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology, 2019.PMID 30514630
- [5]Bullimore MA; Ritchey ER; Shah S; Leveziel N; et al The Risks and Benefits of Myopia Control. Ophthalmology, 2021.PMID 33961969
- [10]Holmes JM; Clarke MP Amblyopia. Lancet, 2006.PMID 16631913
- [12]Németh J, Tapasztó B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol, 2021.PMID 33673740